| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
DOTAP does not have a specific biological target but functions as a cationic lipid transfection reagent. It forms cationic liposomes that electrostatically interact with negatively charged nucleic acids (DNA, RNA) and proteins, facilitating their delivery into eukaryotic cells. The lipid composition and cell type affect the transfection efficiency of DOTAP.
|
|---|---|
| ln Vitro |
In vitro, DOTAP is used to transfect DNA, RNA, and other negatively charged molecules into eukaryotic cells. Its transfection efficiency depends on the lipid composition and cell type. The compound forms cationic liposomes that bind to nucleic acids and facilitate their uptake by cells via endocytosis. It is a standard reagent in molecular biology for gene expression and knockdown studies.
|
| ln Vivo |
In vivo, DOTAP is used for nucleic acid and protein delivery. It can be formulated as liposomes for systemic or local administration to deliver therapeutic genes or siRNAs. The compound's cationic nature allows it to complex with negatively charged payloads and protect them from degradation. In vivo transfection efficiency and biodistribution depend on the formulation and administration route.
|
| Enzyme Assay |
The in vitro transfection protocol using DOTAP involves mixing the cationic lipid with nucleic acids (DNA or RNA) to form lipoplexes. Cells are then incubated with the lipoplexes for a specified period. The transfection efficiency is assessed by measuring the expression of a reporter gene (e.g., GFP, luciferase) or by quantifying gene knockdown using RT-qPCR or Western blotting.
|
| Cell Assay |
Cellular assays using DOTAP involve the transfection of cultured eukaryotic cells with nucleic acids. Cells are seeded in culture plates and treated with DOTAP-nucleic acid complexes. After incubation, cells are analyzed for transgene expression, gene silencing, or protein delivery. Optimal transfection conditions (lipid-to-DNA ratio, cell density, serum concentration) are determined empirically.
|
| Animal Protocol |
In vivo animal studies using DOTAP involve the administration of DOTAP-based liposomes containing nucleic acids or proteins. The liposomes are typically administered via intravenous, intraperitoneal, or intratumoral injection. Tissue distribution, transgene expression, and therapeutic efficacy are assessed at various time points post-administration.
|
| ADME/Pharmacokinetics |
DOTAP is a liposome-forming compound with favorable pharmacokinetic properties for nucleic acid delivery. It can be formulated as liposomes with controlled size and charge. The compound's fatty acid tails contribute to its lipophilic nature and membrane interactions. Specific PK parameters are not detailed in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicity data for DOTAP are not extensively detailed in the available sources. As a cationic lipid, it may exhibit dose-dependent cytotoxicity due to membrane disruption. However, DOTAP is generally considered to have a favorable safety profile for transfection applications at optimized concentrations.
|
| Additional Infomation |
DOTAP is a widely used research reagent for nucleic acid and protein delivery. It is available from various suppliers and is not an approved therapeutic drug. The compound is used in gene therapy, RNA interference, and protein delivery studies. It is intended for research use only and not for human therapeutic use.
|
| Molecular Formula |
C42H80NO4+.CH3O4S-
|
|---|---|
| Molecular Weight |
774.18602
|
| Exact Mass |
757.589
|
| CAS # |
144189-73-1
|
| PubChem CID |
16218742
|
| Appearance |
White to off-white solid powder
|
| LogP |
12.81
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
53
|
| Complexity |
845
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC.COS(=O)(=O)[O-]
|
| InChi Key |
RSMRWWHFJMENJH-LQDDAWAPSA-M
|
| InChi Code |
InChI=1S/C42H80NO4.CH4O4S/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-41(44)46-39-40(38-43(3,4)5)47-42(45)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;1-5-6(2,3)4/h20-23,40H,6-19,24-39H2,1-5H3;1H3,(H,2,3,4)/q+1;/p-1/b22-20-,23-21-;
|
| Chemical Name |
2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;methyl sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~21.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2917 mL | 6.4584 mL | 12.9167 mL | |
| 5 mM | 0.2583 mL | 1.2917 mL | 2.5833 mL | |
| 10 mM | 0.1292 mL | 0.6458 mL | 1.2917 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
